论文部分内容阅读
目的:探讨派罗欣联合胸腺肽对HBeAg阳性慢性乙肝患者的疗效。方法:收治HBeAg阳性慢性乙肝患者96例,分两组,各48例,观察组予以派罗欣联合胸腺肽的治疗措施,对照组单独使用派罗欣的治疗措施,观察两组患者的临床治疗效果。结果:观察组HBeAg转阴率以及HBV-DNA转阴率均显著高于对照组(P<0.05);观察组治疗后的不良反应总发生率6.3%,显著低于对照组的20.8%(P<0.05)。结论:对HBeAg阳性慢性乙肝患者采用派罗欣联合胸腺肽的药物治疗措施达到了更高的转阴率,安全、可靠。
Objective: To investigate the efficacy of Pegasys combined with thymosin on HBeAg-positive chronic hepatitis B patients. Methods: Ninety-six patients with HBeAg-positive chronic hepatitis B were divided into two groups of 48 patients. The observation group was treated with Pegasys combined with thymosin, while the control group was treated with Pegasys alone. The clinical effects of the two groups were observed . Results: The negative rate of HBeAg and the negative rate of HBV-DNA in the observation group were significantly higher than those in the control group (P <0.05). The total incidence of adverse reactions in the observation group was 6.3%, significantly lower than that in the control group (P <0.05). Conclusion: The drug treatment with PEGASYS and thymosin in patients with HBeAg-positive chronic hepatitis B achieves a higher negative conversion rate, which is safe and reliable.